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Background. Alterations in the partly microbiota-dependent carnitine-butyrobetaine (γBB )- 
trimethylamine-N-oxide (TMAO) pathway have been linked to the progression of heart 
failure and atherosclerotic disease. We evaluated if circulating γBB, TMAO and their 
common precursors carnitine and trimethyllysine (TML) were dysregulated after heart 
transplantation and associated with development of cardiac allograft vasculopathy (CAV) and 
acute rejection. Methods. We measured these metabolites in plasma from heart transplant 
recipients with everolimus (EVR)-based (n=32) and standard cyclosporine–based 
immunosuppression (n=30), at different time points and accompanied by assessment of CAV 
by intravascular ultrasound. Results. i) Baseline levels of carnitine, TMAO and TML were 
elevated in heart transplant recipients compared to controls, and TML remained elevated 
throughout the observation period, ii) The microbiota dependent metabolite γBB increased 
steadily during three years follow-up, with a similar decrease in its endogenous precursor 
TML, iii) The increase in γBB and change in TML was associated with change in total 
atheroma volume from baseline to three years, iv) Increase in γBB and carnitine levels from 
baseline to 1 year was associated with increased frequency of acute rejection within the first 
year after heart transplant. Conclusion. Our study reveals alterations of the carnitine-γBB-
TMAO pathway after heart transplant, with increasing levels of γBB being associated with 
acute rejection and increase in total atheroma volume during three years follow-up. Future 
studies should clarify whether interactions between dietary factors, immunosuppressive drugs 
and the gut microbiota could influence acute rejection and CAV development, in order to 






Clinical outcome after heart transplantation (HTx) has improved substantially the last 
decades, but long-term survival is still reduced mainly due to development of cardiac 
allograft vasculopathy (CAV)  1. Whereas both immunological and non-immunological 
mechanisms (e.g., alloimmune responses, non-specific insults including ischemia-reperfusion 
injury, viral infections, and metabolic disorders) are thought to contribute, the mechanisms 
leading to CAV are not fully clarified. Since treatment of CAV is limited, identification and 
prevention of potential triggering and modifiable factors is of clinical major importance 1, 2.   
The gut microbiota, comprising the trillions of bugs inhabiting the gastrointestinal 
tract, may be considered a complex bioreactor with several metabolic and immunological 
roles. Increasing evidence has linked functions and alterations of the gut microbiota to 
cardiometabolic diseases such as atherosclerosis, diabetes and obesity3. The gut microbes 
produce a large range of metabolites which act not only in the gut, but also systemically, and 
the metabolite trimethyl amine-N-oxide (TMAO) was recently introduced as the first 
potentially direct link between the gut microbiota and atherothrombotic disease. 
Trimethylamine (TMA) is produced by the gut microbiota from nutrients containing L-
carnitine, choline and phosphatidylcholine, and is subsequently oxidized by hepatic flavin-
containing monooxygenases to TMAO. Elevated plasma levels of TMAO have in several 
independent cohorts been shown to predict incident myocardial infarction, stroke and all-
cause mortality3-5, as well as poor clinical outcome in heart failure 6, 7. Plasma levels of 
TMAO may be confounded by liver and kidney function,8 and in a recent work, we found γ-
butyrobetaine (γBB), a microbiota-dependent intermediate metabolite in the pathway from 
carnitine to TMAO9, and its endogenous precursor trimethyl lysine (TML), to be even more 
predictive of cardiovascular mortality than TMAO 10. 
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Clinically, CAV resembles coronary heart disease, but is pathologically distinct from 
the usual coronary atherosclerosis and may affect any graft vessel, with concentric, 
progressive thickening along the whole length of the vessels that ultimately leads to ischemia, 
myocardial failure and death. Although the gut microbiota and its products have been 
implicated in the pathogenesis of atherosclerosis, there is no data on the role of TMAO and 
related gut microbiota-derived metabolites in CAV. As transplanted patients have a 
suppressed immune system, the gut microbiota and its metabolites could be of particular 
relevance for development of CAV.  
Gut microbiota changes have been reported after allogenic liver transplantation, 
kidney transplantation and hematopoietic stem cell transplantation, and these changes have 
been potentially linked to complications including acute rejection 11, 12, where direct 
immunological mechanisms and interference with immunosuppressive drugs could be at 
play13.  If such mechanisms are also operating after HTx are however not known 
We hypothesized that the microbiota dependent pro-atherogenic metabolites TMAO 
and γBB, as well as their dietary and endogenous precursors carnitine and TML would be 
elevated after cardiac HTx and associated with development of CAV as well as acute 
rejection during the first year of follow-up. We tested our hypothesis by measuring these 
metabolites in plasma from HTx recipients with everolimus (EVR)-based and standard 





Material and methods 
Study design, population and conduct 
The SCHEDULE trial involved 115 participants. Biobanking was performed in a pre-
specified subgroup subset of these patients of which n=62 had repeated measurements and 
were included in the present study  14. The SCHEDULE (SCandinavian HEart transplant 
everolimus De novo stUdy with earLy calcineurin inhibitor avoidancE) trial was a 
prospective, multicenter, randomized, controlled, open-label trial undertaken at five HTx 
centers in Scandinavia, in which adult de novo HTx recipients (n=115) were randomized in a 
1:1 ratio to (i) low-dose EVR, low-dose cyclosporine (CyA), mycophenolate mofetil (MMF) 
and corticosteroids (CS) with withdrawal of CyA and step up to full dose EVR after 7-11 
weeks or (ii) conventional treatment with CyA, MMF and CS (Figure 1). A detailed 
description of the SCHEDULE trial has been reported previously 14. For comparison of 
carnitine, γBB, TML and TMAO levels, we also included 76 healthy individuals10. The study 
was conducted in compliance with Good Clinical Practice and in accordance with the 2000 
Declaration of Helsinki and Declaration of Istanbul 2008. The appropriate ethics committee 
for each center approved the study and it was registered with clinicalTrials.gov 
(NCT01266148). Written informed consent was obtained from all study participants prior to 
inclusions in the study. 
 
Measurement of TMAO, γBB, carnitine and TML  
Blood samples were available from three time points: 7 weeks (before CyA withdrawal), 12 
months and 3 years  post Tx. Serum levels of TMAO, γBB, carnitine and TML were 
quantified by stable isotope dilution liquid chromatography-tandem mass spectrometry (LC-




Induction therapy with antithymocyte globulin (ATG) was initiated within 12 hours of HTx 
for all included patients and continued for up to 5 days. In the EVR group, EVR was initiated 
at a dose of 0.75 mg twice daily no later than the fifth postoperative day. Everolimus target 
trough levels prior to week 7-11 was 3-6 ng/mL, and after calcineurin inhibitor (CNI) 
withdrawal 6-10 ng/mL. The target trough level of CyA in the EVR group was 75-175 ng/mL 
until week 7-11. CyA elimination took place at week 7 unless ongoing rejection was present 
at that time, in which case discontinuation was allowed to be postponed up to week 11. The 
target dose of MMF was 1500-2000 mg/day until week 7-11, with a target dose of 1000 
mg/day (minimum 750 mg/day) at the time of CyA withdrawal and onwards. In the CNI 
group, the target CyA trough level was 150-350 ng/mL during month 1-3, 100-250 ng/mL 
during month 4-6 and 60-200 ng/mL onwards. The target MMF dose was 2000-3000 mg/day. 
All patients received CS at a minimum dose of 0.1 mg/kg during month 1-3 and 0.05-0.1 
mg/kg at month 4-12. Hereafter, CS could be discontinued at the discretion of the 
investigator14.  
All patients were on statin treatment throughout the study period, unless statin-related 
side effects precluded their use. The decision to initiate antihypertensive treatment was left to 
the discretion of the treating physician.   Cytomegalovirus (CMV) antibody-negative patients 
receiving a graft from a CMV-positive donor were treated with oral valganciclovir for at least 
three months. Furthermore, all of our transplant recipients were prescribed low-dose 
trimethoprim sulfa for the first six months after transplantation. Altogether, 32 % of the 






Intravascular ultrasound  
The pre-defined efficacy variables were changes from baseline in maximal intimal thickness, 
percent atheroma volume, and total atheroma volume as measured by intravascular 
ultrasound (IVUS) 15. These variables are quantitative, surrogate markers for the extent of 
CAV. 
 
Statistical analysis  
Continuous demographics between the treatment groups were compared by unpaired T-test or 
Mann Whitney U test depending on distribution. Proportions were analyzed with the chi-
square test and correlations were calculated using Spearman's rank correlation coefficient. 
Differences in metabolites between controls and HTx patients were analyzed by univariate 
regression with metabolites as dependent (log transformed if necessary), group (i.e. control or 
HTx patients) as fixed and age, sex and creatinine as covariates. For comparing treatment 
effects, univariate repeated-measures ANOVA was performed á priori and paired (paired T-
test) or unpaired (univariate regression adjusting for baseline levels) tests á posteriori at 
individual time-points when appropriate (ANOVA significant). Data from the treatment study 
are given as estimated means with 95% CI. The association between changes in carnitine-
related metabolites and changes in total atheroma volume and acute rejection were analyzed 
by linear and logistic regression, respectively. P values are two-sided and considered 







Baseline characteristic and association with Carnitine-related metabolites 
Baseline characteristics of the patients (n=62) are presented in Table 1. Mean (±SD) age was 
49.8±13.7 years and 26% were female. Median eGFR was 64±15 mL/min/1.73m2 and 
creatinine 104±34 µmol/L. Treatment groups did not differ significantly. As shown in 
Supplemental Table 1, there were few associations between plasma levels of carnitine-related 
metabolites and patient characteristics, although all metabolites correlated with creatinine, 
and TMAO correlated with age and eGFR as previously reported in patients with heart 
failure7. Also TML correlated with eGFR at baseline. 
Circulating levels of Carnitine-related metabolites in HTx patients and healthy controls 
At baseline HTx patients (n=62) had significantly higher plasma levels of carnitine, TMAO 
and TML, but not γBB, compared with healthy controls (n=76) (Figure 1). Controls were 
older (mean age of 66.5±7.1 vs 50.5±13.7, p<0.001), more often female (51% vs 24%, 
p<0.001) and had lower creatinine levels (73±14 vs. 104.1±33.2, p<0.001) but similar BMI 
(25.2±3.1 vs 24.6±3.6, p=0.35) to HTx patients. These factors were adjusted for when 
comparing patients with controls (creatinine was preferred over GFR since the formulae 
includes age and sex). 
Changes over time and effect of treatment on carnitine-related metabolites 
The microbiota-dependent metabolite TMAO decreased from elevated levels at baseline to 
levels comparable with controls at 1 year, and for the EVR group remained at normal levels 
also at 3 years. An opposite pattern was seen for the microbiota-dependent intermediate γBB, 
with levels comparable to controls at baseline, with a steady increase in both treatment 
groups over time, reaching significantly higher levels than at baseline at 3 years in the EVR 
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group. Conversely, TML, an endogenous precursor of γBB, decreased in both groups at 1 and 
3 years, although still elevated compared to healthy controls. Finally, carnitine levels 
remained consistently elevated in HTx patients during follow-up with only minor 
fluctuations. However, no significant differences between the EVR and the CyA arm were 
observed for any of the carnitine-related metabolites (Figure 2). The absolute levels in 
controls and HTx patients during follow-up are given in Supplemental Table 2. 
 The changes in carnitine, γBB and TML from baseline to 1 year and 3 years were not 
significantly associated with the increase in eGFR observed at these time-points (r’s between 
0.02 and 0.23). However, the decline in TMAO was modestly associated with the increase in 
eGFR at 1 year (r=-0.26, p=0.041) and 3 years (r=-0.25, p=0.055) in the HTx population as a 
whole.  
Associations between change in circulating levels of carnitine-related metabolites and total 
atheroma volume 
No associations between baseline levels or change in circulating levels of carnitine-related 
metabolites and CAV as reflected by maximal intimal thickness, percent atheroma volume or 
total atheroma volume were detected (Supplementary Table 1 for correlations at baseline). 
However, changes in total atheroma volume correlated with increase in γBB (r=0.41, 
p=0.002) and change in TML (r=0.30, p=0.029) from baseline to 3 years. Relevant covariates 
are given in Supplemental Table 3. When adjusting for age, sex, treatment, β-blocker and 
changes in LDL cholesterol in a basic linear regression model, the associations between 
carnitine-related metabolites and total atheroma volume were not markedly affected, nor 
when adjusting further for statins, ACE inhibitor/angiotensin receptor blocker, total 
cholesterol, number of infections, ASAT and ASAT (Supplemental Figure 2).  
Associations between carnitine-related metabolites and acute rejection 
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In the current subpopulation of the Schedule trial 59 % experienced one or more acute 
rejections within the first year, of which 34 % where grade 1 and 25 % where grade 2. ROC 
analysis revealed that an increase in levels of carnitine (p=0.013) and γBB (p=0.025), but not 
TMAO and TML, from baseline to 1 year was associated with increased frequency of acute 
rejection in this period (Figure 3A). This was driven by a larger increase of these metabolites 
in patients with Grade 2 rejection (Figure 3B). While having an infection was not associated 
with acute rejection at 1 year, the number of infections was (Supplemental Table 3), and 
therefore included in the basic multivariable adjustment model. Expressing change as 
standardized change (i.e. change/SD) revealed that a 1SD increase in carnitine (OR 2.15 
[1.16 – 4.00] p=0.015) and γBB (OR 2.06 [1.11 – 3.81] p=0.021) was associated with around 
2 times higher likelihood of acute rejection within 1 year. Adjusting for treatment, age, CMV 
mismatch and number of infections even enhanced this association for carnitine (OR 2.39 
[1.15 – 4.96] p=0.020) and γBB (OR 2.25 [1.12 – 4.53] p=0.023), whereas further adjustment 






In this substudy of the SCHEDULE trial, we explored the relationship between the 
microbiota dependent metabolites γBB and TMAO, as well as their dietary and endogenous 
precursors, and the development of CAV and rejection, two important complications after 
HTx. The main results can be summarized as follows: i) Circulating levels of the carnitine-
related metabolites carnitine, TMAO and TML were all elevated in HTx patients at baseline 
compared to controls, and for TML, this elevation was seen throughout the observation 
period, ii) The microbiota dependent metabolite γBB increased steadily during three years 
follow-up, with a similar decrease in its endogenous precursor TML, iii) The increase in γBB 
and change in TML were associated with change in total atheroma volume, but not with any 
other measures of CAV, from baseline to three years, iv) Increase in γBB and carnitine levels 
from baseline to 1 year was associated with increased frequency of acute rejection within the 
first year after HTx.  
Several mechanisms may contribute to the changes in carnitine-related metabolites 
revealed in the present study. As γBB is converted from carnitine by a microbiota-dependent 
mechanism9, changes in gut microbiota over time could explain the steady increase in γBB 
levels during 3 years follow up. The changes in gut microbiota composition after HTx are not 
known, but it was recently reported from a mouse model that immunosuppressive therapy 
including MMF, CS and EVR altered the gut microbiota with decreased Bacteroidetes, 
increased Firmicutes and overgrowth of opportunistic pathogens in feces16. However, herein 
we found that TMAO, which is also produced by microbiota-dependent conversion from 
carnitine and other dietary precursors17, followed an opposite pattern, with decreased 
concentration after 1 year follow-up to levels similar to controls. Notably, TMAO is oxidized 
from trimethylamine (TMA) in the liver and TMAO levels are affected by glycemic control 
and kidney function8. Plasma levels of TMAO were inversely correlated with kidney function 
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both at baseline and during follow-up. Hence, increased renal clearance of TMAO, altered 
liver function, as well as interaction between hepatic oxidation of TMAO and hepatic 
metabolism of drugs may all have contributed to alterations in TMAO levels in the same time 
period. 
Cardiac allograft vasculopathy is a major impediment to long-term survival in heart 
transplant recipients 18, 19. The etiology is likely to be multifactorial. Whereas aspects of the 
disease are probably caused by low grade inflammation and chronic, antibody-mediated 
rejection,18, 19 classical risk factors for coronary artery disease are thought to contribute 20, 21 . 
Although several carnitine-related metabolites including the potential pro-atherogenic 
metabolite TMAO were elevated in heart transplant recipients at baseline, none of them 
predicted the development of CAV during the first three years after HTx. However, the 
increase in γBB and change in TML correlated with an increase in total atheroma volume 
over three years. If this reflects any causal relationship is at present unknown, but the 
association with atheroma volume, and not intimal thickening, could imply that these 
metabolites are associated with traditional atheromatosis rather than the immune component 
of CAV. Intimal thickening is an established predictor of all-cause mortality, myocardial 
infarction, and angiographic abnormalities amongst HTx recipients22, and we found no 
association between this established CAV parameter and any of the carnitine-derived 
metabolites.  
The increase in γBB and change in carnitine levels during the first year after HTx 
were also associated with acute rejection. In addition to microbiota-dependent conversion 
from carnitine, γBB is also produced from the endogenous precursor TML. As carnitine 
levels remained stable whereas TML was reduced, increased conversion from TML to γBB 
after HTx is a possible explanation for the increase in γBB in our study. Whether this 
conversion is also facilitated by the gut microbiota remains unknown. Microbiota changes 
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occur after allogenic liver transplantation, kidney transplantation and hematopoietic stem cell 
transplantation, and these changes may be linked to complications including acute rejection 
11, 12. If such mechanisms are also operating after HTx is not known, although a recent case 
report of CAV and severe mixed rejection following fecal microbial transplant for 
Chlostridium Difficile infection in a 3-year-old male with HTx23 warrants further longitudinal 
studies to clarify whether different gut microbiota profiles could contribute to acute rejection 
and/or CAV. Of interest, number of infections was associated with acute rejections at 1 year 
in our study.  Furthermore, the association between temporal changes in metabolites and 
CAV/rejection could reflect overall changes in microbiota composition rather than specific 
metabolites being relevant for these complications. Alterations in the gut microbiome could 
contribute to rejections through several mechanisms,  including increased immune activation 
and/or impaired immune regulation which could have direct effects on the transplant, but also 
indirect effects through interactions with immunosuppressive drugs13. In Figure 4 we have 
summarized the interaction between carnitine-related metabolites and hypothesized how γBB 
could influence the progression of CAV and acute rejection. 
Of note, the pathway from carnitine to γBB is bidirectional, with TML being 
converted to γBB and further to carnitine10, 17, and several dietary, pharmacological and 
metabolic factors could have contributed to the findings from the present study. L-carnitine is 
a semi-essential nutrient involved in fatty acid oxidation and energy production in the 
mitochondria. Propionyl-L-carnitine prevents early graft dysfunction in allogenic rat kidney 
transplantation24, and L-carnitine supplementation has been associated with a significant 
reduction in all-cause mortality in the setting of acute MI25. Hence, carnitine deficiency at 
baseline could be an alternative explanation for the association between increasing carnitine 
levels and acute rejection. However, as carnitine levels were consistently elevated after HTx, 
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this potential lack of micronutrients would probably be relevant only for a subgroup of 
patients.  
This study has several limitations, including a limited number of patients, and in 
particular a low number of grade II acute rejections, resulting in wide confidence intervals 
and increased risk of type 1 statistical error (supplemental figure 3). Furthermore, when the 
SCHEDULE trial was conducted, the field of quantitative microbiota analysis was in its 
infancy, and we did not collect stool samples. The evidence linking the suggested changes in 
the gut microbiome and the changes in the measures of CAV and the risk of acute rejections 
is therefore circumstantial. Given the lack of statistical power to adjustment for risk factors 
for CAD with relation to microbiota-related progression of CAV, and the lack of stool 
samples, this work may open future areas of investigation for more definitive exploration of 
the gut microbiome after HTx. Of note, the metabolites measured may be influenced by 
various factors, including gut microbiome (TMAO, γBB), diet (carnitine, TMAO, γBB), liver 
function (TMAO), renal function (probably all metabolites) and a lot of concurrent 
medications. However, all of these factors have been adjusted for in multivariate models. In 
the SCHEDULE trial, we used cyclosporine, rather than tacrolimus, in the CNI arm. 
Tacrolimus is now the preferred CNI worldwide. We cannot rule out that the one CNI differs 
from the other with regard to its effect on the microbiome and its associated metabolites. 
However, we are not aware of data supporting this notion.  
Conclusion 
Our study reveals alterations of the carnitine-γBB-TMAO pathway after HTx, with increasing 
levels of γBB being associated with acute rejection and increase in total atheroma volume 
during three years follow-up. It was very recently shown in a mouse model that gut 
microbiota could influence MMF toxicity in the gastrointestinal tract26, and in an Editorial 
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comment, it was underscored that understanding the organized chaos within the gut 
microbiome may open doors to disease modification as part of personalized medicine27. 
Future studies should clarify whether interactions between dietary factors, 
immunosuppressive drugs and the gut microbiota could influence acute rejection and CAV 
development, in order to delineate mechanisms and potential treatment targets.   
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Figure 1. Circulating levels of Carnitine-related metabolites (µmol/L) in HTx patients (n=62) 
at baseline (i.e. x weeks post HTx) compared to healthy controls (n=76). Data are given as 
Tukey plots with outliers and P-values are adjusted for age, gender and creatinine levels. 
Figure 2. Effect of treatment with Cyclosporine  (CyA, n=30) or Everolimus (EVR, n=32) on 
circulating levels of Carnitine-related metabolites (µmol/L) in HTx patients. Data are 
reported as estimated means from the general linear model procedure adjusting for baseline 
levels with 95% CI. The grey area represent the 95%CI from healthy controls. †p<0.05 vs. 
CyA same timepoint. *p<0.05, **p<0.01 vs. baseline. †p<0.05, ††p<0.01, †††p<0.001 
comparing controls and the whole HTx population at the indicated time-points adjusting for 
age, sex and serum creatinine. 
Figure 3. Carnitine-related metabolites and acute rejection. Change in circulating levels of 
carnitine and γBB (both µmol/L) the first year according to acute rejection grade shown as 
Tukey plots with outliers. *p<0.05, **p<0.01 vs. grade 0. 
Figure 4.  Dietary l-carnitine is metabolized into γ- butyrobetaine (γBB) that is further 
converted and metabolized to form trimethylamine-N-oxide (TMAO). This pathway is 
microbiota-dependent, but γBB can also be oxidized from trimethyllysine (TML) 
endogenously. In our proposed model we suggest that γBB could promote progression of 
cardiac allograft vasculopathy (CAV) and acute rejection directly through effects on 
inflammation and activation of endothelial cells. CAV and acute rejection could also have 




Table 1. Baseline clinical and demographic characteristics  





Recipient characteristics     
Age (years) 66.5 ± 7.1* 49.1 ± 12.9 50.5 ±14.9 0.69 
Female 37 (49)* 8 (27) 8 (25) 0.88 
Systolic blood pressure (mmHg)  106.6 ± 17.2 107.9 ± 18.2 0.78 
Diastolic blood pressure (mmHg)  67.3 ± 12.0 67.0 ± 13.1 0.79 
BMI (kg/m2) 25.2 ±3.1 25.5 ± 3.5 23.7 ± 3.6 0.063 
Primary reason for heart transplantation,    0.63 
Idiopathic cardiomyopathy   22 (73) 22 (69)  
Coronary artery disease  7 (23) 7 (22)  
Other  1 (3) 3 (9)  
Left ventricular assist device  7 (23) 9 (28) 0.67 
Medical history     
Diabetes mellitus  6 (20) 3 (9) 0.24 
Chronic obstructive pulmonary disease  1 (3) 1 (3) 0.96 
Hypertension  3 (10) 5 (16) 0.51 
Creatinine 73 ± 14* 102 ± 29 106 ± 39 0.60 
eGFR mL/min/1.73m2  63 ± 14 64 ±17 0.87 
Donor characteristics     
Age (years)  44.4 (12.9) 40.0 ± 14.7 0.21 
Female  9 (30) 13 (41) 0.38 
Cold ischemia time (min)  197 ± 80 185 ± 79 0.57 
Recipient negative /donor positive for         
cytomegalovirus 
 7 (23) 4 (13) 0.26 
Continous data are given as mean±SD (standard deviation) while proportions are reported as n and 
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